Valuation: Acrivon Therapeutics, Inc.

Capitalization 167M 160M 151M 133M 237M 14.47B 265M 1.8B 667M 6.03B 625M 613M 25.52B P/E ratio 2024 *
-2.12x
P/E ratio 2025 * -1.9x
Enterprise value 167M 160M 151M 133M 237M 14.47B 265M 1.8B 667M 6.03B 625M 613M 25.52B EV / Sales 2024 *
-
EV / Sales 2025 * 227x
Free-Float
60.71%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.88%
1 week-17.67%
Current month-11.70%
1 month-2.72%
3 months-32.41%
6 months-26.07%
Current year-10.96%
More quotes
1 week
4.69
Extreme 4.69
6.12
1 month
4.69
Extreme 4.69
8.00
Current year
4.69
Extreme 4.69
8.00
1 year
3.34
Extreme 3.34
11.90
3 years
3.19
Extreme 3.19
25.47
5 years
3.19
Extreme 3.19
25.47
10 years
3.19
Extreme 3.19
25.47
More quotes
Director TitleAgeSince
Chief Operating Officer 45 2018-02-28
Chief Executive Officer 63 2018-03-31
Director of Finance/CFO 54 2022-03-31
Manager TitleAgeSince
Chairman 63 2018-03-31
Director/Board Member 45 2018-02-28
Director/Board Member 54 2020-09-30
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+3.88%-17.67%+47.25% - 167M
+0.05%-1.16%+29.01%-1.03% 47.75B
-0.89%-6.63%-8.93%-19.74% 34.52B
-0.45%-1.71%-0.38%+22.57% 26.11B
-0.08%+4.72%+73.31%+81.97% 16.54B
-2.09%-6.79%-33.62%-30.17% 15.08B
+4.54%-5.03%-62.61%-80.21% 12.28B
+13.36%+28.87% - - 13.19B
-0.99%-10.99%-1.11%-36.19% 10.56B
+1.77%-5.14%-5.96%+95.77% 10.43B
Average +0.71%-2.21%+4.11%+4.12% 18.66B
Weighted average by Cap. +0.05%-1.34%+5.41%+2.26%
See all sector performances

Financials

2024 *2025 *
Net sales - 736K 704K 665K 587K 1.05M 63.79M 1.17M 7.92M 2.94M 26.56M 2.76M 2.7M 113M
Net income -81.62M -78.15M -73.82M -65.1M -116M -7.08B -130M -879M -326M -2.95B -306M -300M -12.48B -109M -104M -98.25M -86.64M -154M -9.42B -172M -1.17B -434M -3.92B -407M -399M -16.61B
Net Debt - -
More financial data * Estimated data
Logo Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Employees
60
More about the company
Date Price Change Volume
25-02-13 5.360 $ +3.88% 16,113
25-02-12 5.160 $ +5.09% 35,103
25-02-11 4.910 $ -12.63% 79,290
25-02-10 5.620 $ -6.64% 26,877
25-02-07 6.020 $ -7.53% 31,865

Delayed Quote Nasdaq, February 13, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.360USD
Average target price
21.11USD
Spread / Average Target
+293.86%
Consensus

Quarterly revenue - Rate of surprise